Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00498-x

Post hoc analysis from the FINCH 1 study highlights filgotinib as a potential beneficial treatment option for patients with RA who have had inadequate response to MTX and have high risk of disease progression and poor prognosis.

The 2019 EULAR management guidelines for RA recommend early treatment escalation for patients with predefined poor prognostic factors (PPFs) including, seropositivity (defined by RF or CCP), high baseline hsCRP, high baseline disease activity, and extant bone erosion at disease onset. As such, Combe, et al. evaluated the efficacy and safety of filgotinib in patients with all four PPFs, versus those with fewer.